Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when ELAB files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: ELAB PMGC Holdings Inc. 8-K

PMGC Holdings subsidiary NorthStrive Biosciences issues press release under Reg FD

Filed April 28, 2026 · Period ending April 28, 2026 · ~1 min read

1 key change 1 section

Key Changes

  • low

    NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings, issued a press release on April 28, 2026. The content is furnished as an exhibit but not disclosed in the 8-K body itself.

Summary

PMGC Holdings filed a routine 8-K to disclose that its wholly owned subsidiary, NorthStrive Biosciences, issued a press release on April 28, 2026. This filing is made under Regulation FD (Fair Disclosure), which requires companies to publicly release material information simultaneously to all investors rather than selectively. The actual content of the press release is provided only in Exhibit 99.1, which is not included in the main filing body.

Without access to the exhibit, the materiality and substance of the announcement cannot be assessed. Retail investors should review the press release exhibit directly on the SEC website to understand what NorthStrive announced and whether it contains material business developments, clinical trial results, partnership announcements, or other substantive updates that could impact PMGC Holdings' valuation.

Section-by-Section Diff

Event · Item 7.01 — Regulation FD Disclosure

~100 words

Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.

1 Added
Show 1 minor / wording change
Added Press release issuance low

Added in current filing · verify on EDGAR →

On April 28, 2026, NorthStrive Biosciences Inc., a Delaware corporation and wholly owned subsidiary of PMGC Holdings Inc. (the “Company”) issued a press release, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The company disclosed that its wholly owned subsidiary NorthStrive Biosciences issued a press release on April 28, 2026. The actual content of the press release is provided in Exhibit 99.1, which is not included in the 8-K body text. This is a Regulation FD disclosure, meaning the information is being publicly released to ensure fair disclosure to all investors simultaneously.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify